New answers to old questions: Pioneering therapies for neurological disorders

Neurometa Therapeutics is developing first-in-class disease-modifying treatments for high unmet need neurological conditions

Explore our pipeline Learn about our science

ABOUT

Three promising programs. One patient-focused mission.

Neurometa Therapeutics is advancing three innovative small molecule programs designed to deliver category-leading medicines for serious neurological disorders.

By pursuing fundamental disease mechanisms through novel targets, we aim to create transformative treatments that go beyond symptom relief to truly improve the lives of those living with devastating diseases. The programs offer broad therapeutic impact and efficient development synergies.

Backed by an experienced team, Neurometa has strong momentum: securing competitive US Department of Defense funding, achieving robust results in pre-clinical disease models with excellent biomarker data, and earning acceptance into the prestigious NIH HEAL Initiative.

ORIGIN

Grounded in decades of discovery

Neurometa Therapeutics builds on decades of pioneering research in human genetics, biomarkers, advanced disease models, and quantitative systems pharmacology. This rich foundation has uncovered novel therapeutic approaches that are now being translated into promising medicines. The company bridges the groundbreaking work of original scientific innovators with expert drug developers who will guide these programs through clinical testing, ultimately delivering meaningful new treatments to patients living with serious neurological disorders.

Team

A winning combination of scientific and business experience

Preben Bruun-Nyzell

Co-Founder & CEO

Co-founder of 2A Pharma. Chair of Apoglyx. Former CFO Qatalum ($1.5bn sales, $6bn balance sheet). Prior roles at Roche, Arqaam Capital, PwC, Accenture.

Steinunn S. Helgudóttir, PhD

Co-Founder & CSO

PhD in Neuroscience, Aalborg University. 2025 Kamma Prize laureate.

John Nieland, PhD

Co-Founder & CIO

Associate Professor, Aalborg University. Former Director of Research, Medigene AG. Co-inventor of foundational Etomoxir/CPT1 work.

Anne S. Mørkholt, PhD

Co-Founder & Head of Operations

PhD Neuroscience, Aalborg University — funded by the Lundbeck Foundation.

Neil Benson, PhD

Quantitative Systems Pharmacology and PK/PD Modeling Consultant

Founder and CEO, Xenologiq and Sevenless Therapeutics. PKPD Lead, Pain at Pfizer. Former Head of Systems Pharmacology at Pfizer. Recipient of the Pfizer Upjohn Award for Innovation.

Kristina Bruun-Nyzell

Head of Business Development

Innovation strategist with 30+ years of experience supporting stakeholder engagement and partnerships.

Morten Fjordholt

Strategic Advisor, Safety Assessment

Molecular biologist and pharmaceutical toxicologist (20+ years). Board member of the Danish Toxicology & Pharmacology Society.

Fredrik Lehmann, PhD, MBA

CMC Consultant

Medicinal chemist (20+ years). Serial biotech entrepreneur. Former Venture Partner at Industrifonden, EIR Ventures, and Sound Bioventures.

Scientific Advisory Board

World-renowned KOLs in ALS and neurology

Merit Cudkowicz, MD

Scientific Advisory Board

Executive Director, Mass General Brigham Neuroscience Institute. Director, Healey & AMG Center for ALS. Professor of Neurology, Harvard Medical School.

Caroline Ingre, MD, PhD

Scientific Advisory Board

Adjunct Professor and Head of ALS Clinical Research, Karolinska Institutet, Stockholm. Board Member of TRICALS.

Claus Sundgreen, MD

Scientific Advisory Board

CMO / Medical Director with extensive ALS clinical experience. Previously VectorY, Orphazyme, TikoMed, NeuroSearch, Schering-Plough, Nycomed.

Arnar Astradsson, MD, PhD

Scientific Advisory Board

Consultant Neurosurgeon, Rigshospitalet (Copenhagen) and Harvard Medical School.

Pipeline

Three programs. Designed for lasting impact.

We are advancing a focused pipeline of three programs designed to deliver category-leading medicines that target key drivers of serious neurological disorders, with the goal of delivering meaningful, lasting improvements to patients’ lives.

ProgramTarget / PathwayINDICATIONSModality & AdministrationStage

MITOMETIN

CPT1A / Neurometabolism

ALS and Parkinson's disease

Small molecule, oral

DiscoveryLead OptIND-enablingPhase 1Phase 2/3

SOSIN

SOS1 / RAS-signaling

Neurofibromatosis and pain

Small molecule, oral

DiscoveryLead OptIND-enablingPhase 1Phase 2/3

HEATMOD

HSP70 / Immune tolerance

Neuroinflammation and autoimmunity

Small molecule, oral

DiscoveryLead OptIND-enablingPhase 1Phase 2/3

MITOMETIN

Amyotrophic Lateral Sclerosis (ALS)

Pathology shared with Parkinson's disease, multiple sclerosis, and Alzheimer's disease

Preclinical

Fully owned. Composition-of-matter patents filed in 2022; protection to 2042+.

Mechanism

Selective CPT1A inhibition — restores glucose oxidation, reduces excessive fatty-acid oxidation and ROS.

Unmet medical need & differentiation

ALS progresses rapidly with ~50% mortality within 2 years; current treatments offer only modest survival benefit and no meaningful disease modification.
Neurometa targets neurometabolic dysregulation via CPT1A inhibition, a genetically validated pathway and core hallmark of ALS that remains unexplored by other therapies.
Our first-in-class CPT1A inhibitor for neurodegeneration is clearly differentiated from other approaches.
We are developing an oral small molecule with potential to become the new standard of care by addressing a fundamental, untargeted driver of disease.

SOSIN

Neurofibromatosis Type 1 (NF1)

Pain (NIH HEAL Initiative)

Preclinical

Exclusive worldwide license. Composition-of-matter patents on lead (2022) and back-up (2025) series.

Mechanism

SOS1 inhibition upstream of MEK — directly reduces RAS activation at the root of pathway hyperactivity.

Unmet medical need & differentiation

High unmet need in NF1: debilitating nerve tumors and pain with only two approved MEK inhibitors, both limited by significant side effects and high discontinuation rates.
More than 130,000 people living with NF1 in the 7 major markets with blockbuster potential.
Novel SOS1 inhibitor acting upstream in the validated RAS/MEK pathway.
Differentiated by potentially avoiding MEK class toxicities while maintaining efficacy on tumor growth.

HEATMOD

Neuroinflammation & Autoimmunity

Broad blockbuster potential across neurology and immunology

Discovery

Fully owned. AI-driven target and compound modeling led by the Neurometa team.

Mechanism

Modulation of extracellular HSP70 — promotes tolerogenic, not suppressed, immunity.

Unmet medical need & differentiation

Most current therapies rely on broad immunosuppression with serious long-term risks.
Neurometa is developing a first-in-class small molecule drug that induces antigen-specific immune tolerance by modulating extracellular HSP70i signaling.
Clearly differentiated from broad immunosuppressants and cell-based tolerance strategies; no approved drugs currently achieve antigen-specific tolerance.
Potential to transform treatment by replacing non-specific suppression with targeted immune reprogramming.

A caring clinician with a young patient and an older adult in a neurology clinic

Patients

Patient-centered by design

Patients are at the heart of everything we do. From the earliest stages of research through clinical development, we actively engage with patient advocacy groups to ensure our development efforts reflect the lived experience of people with the conditions for which we develop new medicines.

Empathy-first development delivering disease-modifying therapies with better outcomes for patients and their families.
Engagement with patient advocacy groups as experts and partners by experience.
Commitment to a patient-centric trial design that meaningfully incorporates patient perspectives and preferences into every aspect of the studies.

News & Media

What's happening at Neurometa

Latest news

No news yet.

Contact

Let's talk

Whether you're an investor, potential partner, patient advocate, or journalist — we'd love to hear from you.